Safety, Tolerability, Pharmacokinetics, and Efficacy of Acapatamab in Subjects With mCRPC
A phase 1 study evaluating the safety, tolerability, pharmacokinetics, and efficacy of prostate specific membrane antigen half-life extended bispecific T-cell engager acapatamab in subjects with metastatic castration-resistant prostate cancer, and to determine the maximum tolerated dose (MTD) or recommended phase 2 dose (RP2D).
Metastatic Castration-resistant Prostate Cancer|Prostate Cancer
DRUG: acapatamab|DRUG: Pembrolizumab|DRUG: Etanercept|DRUG: Cytochrome P450 (CYP) Cocktail
Number of participants with dose-limiting toxicity, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Number of participants with treatment-emergent adverse events, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Number of participants with treatment-related adverse events, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Number of participants with clinically significant changes in vital signs, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Number of participants with clinically significant changes in electrocardiogram (ECG), Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Number of participants with clinically significant changes in clinical laboratory tests, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years
Maximum serum concentration (Cmax) of acapatamab, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Minimum serum concentration (Cmin) of acapatamab, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Area under the concentration-time curve (AUC) over the dosing interval of acapatamab, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Accumulation ratio of acapatamab, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Half-life of acapatamab, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Objective response (OR), Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Prostate-specific antigen (PSA) response, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Duration of response (DOR) (radiographic and PSA), Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Percentage of participants experiencing a response based on 68Gallium (68Ga)-prostate-specific membrane antigen (PSMA)-11 positron emission tomography (PET)/computed tomography (CT) response evaluations, Parts 1, 2 and 3 only., Up to 3 years|Percentage of participants experiencing a response based on 18F-fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) response evaluations, Parts 1, 2 and 3 only., Up to 3 years|Change in time to progression (radiographic and PSA), Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Progression-free survival (PFS) (radiographic and PSA), Parts 1, 2, 3, 4, 5, and 6 of the study., Up to 3 years|1, 2 and 3-year overall survival (OS), Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Percentage of participants experiencing circulating tumor cells (CTC) response, Parts 1, 2, 3, 4, 5, and 6 of the study. CTC response defined as CTC0 (reduction of CTCs \> 0 to 0) or CTC conversion (≥ 5 CTCs/7.5 mL blood to ≤ 4 CTCs/7.5 mL blood), Up to 3 years|Other PCWG3-recommended endpoints - time to symptomatic skeletal events, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Other PCWG3-recommended endpoints - lactate dehydrogenase [LDH] levels, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Other PCWG3-recommended endpoints - hemoglobin levels, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Other PCWG3-recommended endpoints - neutrophil-to-lymphocyte ratio, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Other PCWG3-recommended endpoints - urine N-telopeptide levels, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Other PCWG3-recommended endpoints - alkaline phosphatase [total, bone] levels, Parts 1, 2, 3, 4, 5, and 6 of the study, Up to 3 years|Maximum serum concentration (Cmax) of acapatamab when administered with CYP enzymes, Part 6 only., Up to 3 years|Area under the concentration-time curve over a 24-hour period (AUC24) of acapatamab when administered with CYP enzymes, Part 6 only., Up to 3 years|Half-life of acapatamab when administered with CYP enzymes, Part 6 only., Up to 3 years
This is a phase I, first-in-human study to evaluate the safety and tolerability of acapatamab; a half-life extended (HLE) bispecific T-cell engager (BiTE®) construct, alone and in combination with pembrolizumab, etanercept prophylaxis and cytochrome P450 (CYP) phenotyping cocktail in subjects with metastatic castration-resistant prostate cancer.